Oprozomib and Dexamethasone,in Combination With Lenalidomide or Oral Cyclophosphamide to Treat Newly Diagnosed Multiple Myeloma
Public ClinicalTrials.gov record NCT01881789. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone, in Combination With Lenalidomide or Oral Cyclophosphamide in Patients With Newly Diagnosed Multiple Myeloma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objectives of this study included the following: Phase 1b: * To establish the maximum tolerated dose (MTD) of oprozomib given in combination with lenalidomide and dexamethasone (ORd) or with cyclophosphamide and dexamethasone (OCyd) * To evaluate the safety and tolerability of oprozomib and dexamethasone administered in combination with lenalidomide or oral cyclophosphamide Phase 2: * To estimate the antitumor activity of each combination regimen, as measured by overall response rate (ORR) and complete response rate (CRR) * To evaluate the safety and tolerability of each combination regimens, as assessed by the type, incidence, severity and seriousness of adverse events, and abnormalities in selected laboratory analytes
Study identification
- NCT ID
- NCT01881789
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 22 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 27, 2013
- Primary completion
- Sep 22, 2019
- Completion
- Sep 22, 2019
- Last update posted
- Nov 13, 2022
2013 – 2019
United States locations
- U.S. sites
- 14
- U.S. states
- 12
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Clearview Cancer Institute | Huntsville | Alabama | — | — |
| Providence St. Joseph's Hospital | Burbank | California | — | — |
| David Geffen School of Medicine at UCLA | Los Angeles | California | — | — |
| Monterey Bay Oncology Corp DBA Pacific Cancer Care | Salinas | California | — | — |
| Colorado Blood Cancer Institute | Denver | Colorado | — | — |
| H. Lee Moffit Cancer Center & Research Institute | Tampa | Florida | — | — |
| University of Chicago Medical Center | Chicago | Illinois | — | — |
| Indiana University Health Melvin and Bren Simon Cancer Center | Indianapolis | Indiana | — | — |
| Center for Cancer & Blood Disorders | Bethesda | Maryland | — | — |
| The University of North Carolina at Chapel Hill | Chapel Hill | North Carolina | — | — |
| Cleveland Clinic | Cleveland | Ohio | — | — |
| University of Texas M.D. Anderson Cancer Center | Houston | Texas | — | — |
| Fred Hutchinson Cancer Research Center | Seattle | Washington | — | — |
| Froedtert Hospital and the Medical College of Wisconsin | Milwaukee | Wisconsin | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01881789, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 13, 2022 · Synced Sep 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01881789 live on ClinicalTrials.gov.